URGN
UroGen Pharma Ltd
41.60$
-2.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 23.9% | -117.3% | -3,309.8% | -394,538.9% | -897.4% | -176.7% | -136.1% | -92.3% | -107.0% | -148.0% | |
| – | – | 1.2% | 2.5% | 37.0% | 7,355.6% | 17.3% | 3.7% | 2.8% | 2.1% | 1.3% | 2.2% | |
| – | – | 11.2% | 77.2% | 2,716.5% | 166,483.3% | 237.5% | 48.1% | 16.4% | 11.3% | 14.5% | 10.9% | |
| – | – | 26.9% | 79.3% | 2,725.4% | 166,483.3% | 228.2% | 48.1% | 17.8% | – | – | – | |
| – | – | 6.9% | 46.1% | 635.1% | 24,000.0% | -54.0% | -27.3% | -9.8% | 4.0% | 5.5% | -25.4% | |
| – | – | 4.0% | 3.3% | 49.6% | 1,805.6% | 10.3% | 1.6% | 0.4% | 0.2% | 0.3% | 0.3% | |
| – | – | -4.5% | -445.9% | 3,128.3% | -808,850.0% | 790.2% | 8.5% | 1.6% | -1.2% | -22.8% | 56.1% | |
| – | – | 3.3% | 755.4% | 5,907.4% | 918,055.6% | 140.1% | -0.2% | 2.1% | – | – | – | |
| – | – | – | – | -19.1% | – | 0.4% | 0.0% | 148.8% | 0.0% | 27.1% | -1.7% | |
| – | – | -0.1% | 754.9% | 5,888.4% | 918,055.6% | 140.1% | 150.5% | 150.9% | 141.4% | 215.3% | 36.4% | |
| – | – | 19.3% | 191.7% | 5,706.9% | -285,333.3% | 32.9% | -17.7% | 16.5% | 47.9% | 85.4% | -55.5% | |
| – | – | 19.9% | -120.6% | -3,359.4% | -396,344.4% | -907.7% | -178.3% | -136.4% | -92.6% | -107.4% | -148.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.